Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B1IC
|
|||
| Former ID |
DIB007423
|
|||
| Drug Name |
CR8020
|
|||
| Synonyms |
H3N2 and H7N7 influenza monoclonal antibody therapy, Crucell
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Influenza virus infection [ICD-11: 1E30-1E32] | Phase 2 | [1] | |
| Influenza A virus infection [ICD-11: 1E30] | Investigative | [2] | ||
| Company |
Crucell
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Influenza Hemagglutinin (Influ HA) | Target Info | . | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01992276) Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection. U.S. National Institutes of Health. | |||
| REF 2 | The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. | |||
| REF 3 | Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J Virol. 2014 Dec;88(23):13580-92. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.